期刊文献+

HIV-1 B'亚型gag-env融合基因的DNA疫苗构建和免疫原性分析 被引量:3

Immunogenicity of a new DNA vaccine against HIV-1 B' clade
原文传递
导出
摘要 目的构建HIV-1 B’亚型中国流行株gag和env融合基因的DNA疫苗,对其免疫原性进行研究。方法根据已报道的HIV-1 B’亚型RL42分离株gag和env基因的氨基酸序列按哺乳动物密码子使用频率进行优化并人工合成基因,插入真核表达载体pDRVISV1.0中,构建表达RL42 gag- env融合蛋白的DNA疫苗,pSVRL/GE。用Western blot和抗gag p55抗体细胞内染色的方法体外检测pSVRL/GE的表达效率。DNA疫苗pSVRL/GE免疫BALB/c小鼠后,用ELISPOT检测小鼠的细胞免疫反应。结果限制性内切酶鉴定表明融合基因已成功插入pDRVISV1.0载体中,Western blot证实融合基因可有效表达融合蛋白;细胞内染色结果表明,pSVRL/GE转染的293T细胞中49.8%表达gag p55,荧光强度均值为924;而空载体pDRVISV1.0转染的293T细胞中非特异背景染色只有0.5%。经免疫的小鼠脾细胞体外用H-2d限制性表位肽AMQMLKET刺激后,ELISPOT检测显示,pSVRL/GE免疫小鼠每106脾细胞形成226个斑点(SD=140),而空载对照组每106脾细胞形成29个斑点(SD=16)(P< 0.05)。结论所构建的DNA疫苗pSVRL/GE可高效表达相应抗原蛋白,并可有效激活机体的细胞免疫反应。 Objective To construct a DNA vaccine against gag and env gene of Thailand B clade (B') and to study its immunogenicity. Methods A DNA vaccine, pSVRL/GE, was constructed by inserting a synthetic fusion gene, which were humanized and synthesized according to the amino acid sequence of the gag and env genes of HIV-1 B' isolate RL42, into plasmid vector pDRVISV1.0. Western blot and intracellular anti-gag p55 staining were used to determine the expression efficacy in vitro. BALB/c mice were immunized with the DNA vaccine and thereafter T cell immune responses were determined with ELISPOT. Results Enzyme-restricted digestion showed that the fusion gene was successfully inserted into vector pDRVISV1.0. Fluorescence-activated cell sorter (FACS) analysis after intracellular staining displayed 49.8% pSVRL/GE-tmnsfected 293T cells was gag p55 positive with a mean fluorescence intensity(MFI) of 924, whereas the controls only showed 0.5% positive cells with a mean MFI of 78.67. Immunization with DNA vaccine pSVRL/GE( n = 5) stimulated 226(SD = 140) spot forming cells(SFCs) per 106 splenocytes targeting at the H-2d restricted epitope AMQMLKEF, whereas the control group only showed 29(SD= 16) SFCs per 106 splenocytes(P 〈 0.05). Conclusion The DNA vaccine pSVRL/GE is able to efficiently expresse its inserted fusion gene and induce vigrous cellular immune responses.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2006年第7期654-658,共5页 Chinese Journal of Microbiology and Immunology
关键词 HIV-1 B′亚型 DNA疫苗 HIV-1 B' clade DNA vaccine
  • 相关文献

参考文献10

  • 1AIDS epidemic update,Dec.2004,UNAIDS,World Health Organization.
  • 2国务院防治艾滋病工作委员会办公室.中国艾滋病防治联合评估报告(2004)[R].,2004,12..
  • 3Morgenstern B,Frech K,Dress A,et al.DIALIGN:Finding local similarities by multiple sequence alignment.Bioinformatics,1998,14:290-294.
  • 4Graf M,Shao Y,Zhao Q,et al.Cloning and characterization of a virtually full-length HIV type 1.genome from a subtype B'-Thai strain representing the most prevalent B-clade isolate in China.AIDS Res Hum Retroviruses,1998,14(3):285-288.
  • 5Zolotukhin S,Potter M,Hauswirth WW,et al.A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.J Virol,1996,70(7):4646-4654.
  • 6萨姆布鲁克 拉塞尔.分子克隆实验指南(第三版)[M].北京:科学出版社,2002..
  • 7Finzi D,Siliciano RF.Viral dynamics in HIV-1 infection.Cell,1998,93(5):665-671.
  • 8Kwong PD,Wyatt R,Robinson J,et al.Structure of an HIV gp120envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.Nature,1998,393:648-659.
  • 9McCutchan FE.Understanding the genetic diversity of HIV-1.AIDS,2000,14(Suppl 3):S31-S44.
  • 10Parren PW,Moore JP,Burton DR,et al.The neutralizing antibody response to HIV-1:viral evasion and escape from humoral immunity.AIDS,1999,13(Suppl A):S137-S162.

共引文献23

同被引文献26

  • 1邵一鸣,罗夫·伟格拿,汉思·渥夫.HIV-1亚型间(C/B^*)基因组和其用途:中国,CN1423698[P].2003-6-11.
  • 2BURGERS WA, VAN HARMELEN JH, SHEPHARD E, et al. Design and preclinical evaluation of a multigene human immunod- eficiency virus type 1 subtype C DNA vaccine for clinical trial [J]. J Gen Virol,2006,87 (Pt2) :399 -410.
  • 3WALKER LE, VANG L, SHEN X,et al. Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes [ J ]. Vaccine ,2009,27 ( 50 ) :7087 - 7095.
  • 4SNODIN DJ,RYLE PR. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals[ J]. Bio Drugs ,2006,20( 1 ) :25 - 52.
  • 5CORBETT M,BOGERS WM, HEENEY JL,et al. Aerosol immu- nization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic [ J ]. Proc Natl Acad Sci, 2008, 105 ( 6 ) : 2046 - 2051.
  • 6HUO Y,LI B,ZHANG Y,et al. Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein [ J]. Regul Toxicol Pharmacol,2007,49 ( 1 ) :63 -74.
  • 7GHIRARDELLO A,VILLALTA D, MOROZZI G,et al. Diagnos- tic accuracy of currently available anti-double-stranded DNA anti- body assays. An Italian multicentre study[ J]. Clin Exp Rheuma- tol,2011,29( 1 ) :50 - 56.
  • 8BAHARI MH, MAHMOUDI M, AZEMI A,et al. Early diagnosis of systemic lupus erythmatosus using ANN models of dsDNA binding antibody sequence data [ J ]. Bioinformation, 2010, 5 (2) :58 -61.
  • 9Burgers W A, Van Harmelen J H, Shephard E, et al. De- sign and preclinical evaluation of a multigene human immuno- deficiency virus type 1 subtype C DNA vaccine for clinical tri- al [J] . J Gen Virol, 2006, 87 (Pt2): 399-410.
  • 10邵一鸣,罗夫·伟格拿,汉思·渥夫.HIV-1亚型间(C/B)基因组和其用途:中国,CNl423698[P].2003-6-11.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部